Idarucizumab
Idarucizumab
Idarucizumab (pronounced as "eye-dah-roo-siz-oo-mab") is a monoclonal antibody specifically designed for the reversal of the anticoagulant effects of dabigatran, a direct thrombin inhibitor.
Etymology
The name "Idarucizumab" is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature for therapeutic proteins, particularly monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the "-izu-" infix suggests its humanized nature.
Usage
Idarucizumab is used in patients who are on dabigatran and have uncontrolled bleeding or need to undergo an urgent procedure. It works by binding to dabigatran and its metabolites, neutralizing their anticoagulant effect.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Dabigatran: A direct thrombin inhibitor used as an anticoagulant.
- Thrombin inhibitor: A type of drug that prevents the formation of blood clots by inhibiting the action of thrombin.
- Anticoagulant: A substance that prevents coagulation (clotting) of blood.
See Also
External links
- Medical encyclopedia article on Idarucizumab
- Wikipedia's article - Idarucizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski